Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: AMRX

Amneal Pharmaceuticals, Inc.

Healthcare | Drug Manufacturers - Specialty & Generic

No licensed closing price on file for AMRX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$0.48

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a specialty and generic drug manufacturer. Figures from SEC EDGAR; updated 2026-10-21 02:46 UTC.

What Amneal Pharmaceuticals, Inc. does

Amneal Pharmaceuticals is a diversified global biopharmaceutical company that develops, manufactures, markets, and distributes essential medicines through three main segments: Affordable Medicines (which includes generic drugs, injectables, and biosimilars), Specialty (branded pharmaceuticals for central nervous system and endocrine disorders), and AvKARE (a pharmaceutical distributor for U.S. federal, retail, and institutional markets). The company operates principally in the United States, India, and Ireland as a holding company.

Summarized from Amneal Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$0.48
Return on equity-101.78%
Debt/equity77.83

Revenue, margins & earnings

FY2021 Taxes & interest: $140MFY2021 Operating expenses: $616MFY2021 Cost of revenue: $1.32B$2.09BFY2021FY2022: net loss $271M on revenue $2.21B$2.21BFY2022FY2023: net loss $84M on revenue $2.39B$2.39BFY2023FY2024: net loss $117M on revenue $2.79B$2.79BFY2024FY2025 Net income: $72MFY2025 Taxes & interest: $322MFY2025 Operating expenses: $719MFY2025 Cost of revenue: $1.91B$3.02BFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →
Net income for FY2024 is the filer’s available-to-common figure (net of preferred dividends) — the filer tags no parent net income for those years.

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-21
  • 2026-09-21DirectorGift-20,445—
  • 2026-09-14DirectorStock OptionOption exercise-20,445—
  • 2026-09-14DirectorOption exercise20,445$295.4K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Amneal Pharmaceuticals, Inc. do?

Amneal Pharmaceuticals, Inc. is a specialty and generic drug manufacturer, listed on NASDAQ as AMRX.

When did AMRX last file with the SEC?

Amneal Pharmaceuticals, Inc.'s most recent SEC filing on record is a 10-Q filed 2026-05-07. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 02:46 UTC. This page is also available as JSON at /api/data?ticker=AMRX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for AMRX and 5,000+ tickers.

Create a free account — keep AMRX
For your agent
GET /api/data?ticker=AMRX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt